These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 11818201)

  • 21. Pilot study assessing a seven-day continuous intrathecal topotecan infusion for recurrent or progressive leptomeningeal metastatic cancer.
    Tran HC; Gardner S; Weiner HL; Liebes LF; Finlay JL
    J Oncol Pharm Pract; 2014 Jun; 20(3):229-32. PubMed ID: 23929729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5-FU-pretreated patients with colorectal cancer.
    Hütter G; Szélenyi H; Deckert PM; Keilholz U; Thiel E
    Cancer Chemother Pharmacol; 2004 Aug; 54(2):178-84. PubMed ID: 15114411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Open-label simultaneous radio-chemotherapy of glioblastoma multiforme with topotecan in adults.
    Gross MW; Altscher R; Brandtner M; Haeusser-Mischlich H; Chiricuta IC; Siegmann AD; Engenhart-Cabillic R
    Clin Neurol Neurosurg; 2005 Apr; 107(3):207-13. PubMed ID: 15823676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Postoperative radiotherapy of glioblastoma multiforme: analysis and critical assessment of different treatment strategies and predictive factors.
    Piroth MD; Gagel B; Pinkawa M; Stanzel S; Asadpour B; Eble MJ
    Strahlenther Onkol; 2007 Dec; 183(12):695-702. PubMed ID: 18040615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma.
    Voloschin AD; Betensky R; Wen PY; Hochberg F; Batchelor T
    J Neurooncol; 2008 Jan; 86(2):211-5. PubMed ID: 17896078
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II trial of combined modality therapy with concurrent topotecan plus radiotherapy followed by consolidation chemotherapy for unresectable stage III and selected stage IV non-small-lung cancer.
    Seung SK; Ross HJ
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):802-9. PubMed ID: 18762390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
    Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A
    Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Weekly topotecan for recurrent platinum resistant ovarian cancer.
    Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
    Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
    Seiden MV; Ng SW; Supko JG; Ryan DP; Clark JW; Lynch T; Huang KC; Kwiatkowski D; Skarin A; Eder JP
    Clin Cancer Res; 2002 Mar; 8(3):691-7. PubMed ID: 11895897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group.
    Hochster H; Wadler S; Runowicz C; Liebes L; Cohen H; Wallach R; Sorich J; Taubes B; Speyer J
    J Clin Oncol; 1999 Aug; 17(8):2553-61. PubMed ID: 10561322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Results of a trial with topotecan dose escalation and concurrent thoracic radiation therapy for locally advanced, inoperable nonsmall cell lung cancer.
    Graham MV; Jahanzeb M; Dresler CM; Cooper JD; Emami B; Mortimer JE
    Int J Radiat Oncol Biol Phys; 1996 Dec; 36(5):1215-20. PubMed ID: 8985046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topotecan as a continuous infusion over 14 days in recurrent ovarian cancer patients.
    Denschlag D; Watermann D; Hörig K; Kissel C; Tempfer C; Gitsch G
    Anticancer Res; 2004; 24(2C):1267-9. PubMed ID: 15154658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II evaluation of topotecan for pediatric central nervous system tumors.
    Blaney SM; Phillips PC; Packer RJ; Heideman RL; Berg SL; Adamson PC; Allen JC; Sallan SE; Jakacki RI; Lange BJ; Reaman GH; Horowitz ME; Poplack DG; Balis FM
    Cancer; 1996 Aug; 78(3):527-31. PubMed ID: 8697400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.
    Garst J; Herndon JE; Shafman T; Campagna L; Blackwell S; Padilla K; Bjurstrom T; Andrews C; Maravich-May D; Anderson E; Crawford J
    Clin Drug Investig; 2006; 26(5):257-66. PubMed ID: 17163259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke.
    Friedman HS; Kerby T; Fields S; Zilisch JE; Graden D; McLendon RE; Houghton PJ; Arbuck S; Cokgor I; Friedman AH
    Cancer; 1999 Mar; 85(5):1160-5. PubMed ID: 10091802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A prospective phase II study of induction carboplatin and vinorelbine followed by concomitant topotecan and accelerated radiotherapy (ART) in locally advanced non-small cell lung cancer (NSCLC).
    Patel SH; Ajlouni M; Chapman R; Lu M; Movsas B; Kim JH
    J Thorac Oncol; 2007 Sep; 2(9):831-7. PubMed ID: 17805061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
    Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
    Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002.
    Miller AA; Wang XF; Bogart JA; Hodgson LD; Rocha Lima CM; Radford JE; Vokes EE; Green MR;
    J Thorac Oncol; 2007 Jul; 2(7):645-51. PubMed ID: 17607121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.
    Herzog TJ; Powell MA; Rader JS; Gibb R; Mutch DG
    Gynecol Oncol; 2006 Nov; 103(2):637-41. PubMed ID: 16781766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas: results of a French Society of Paediatric Oncology Phase II Study.
    Bernier-Chastagner V; Grill J; Doz F; Bracard S; Gentet JC; Marie-Cardine A; Luporsi E; Margueritte G; Lejars O; Laithier V; Mechinaud F; Millot F; Kalifa C; Chastagner P
    Cancer; 2005 Dec; 104(12):2792-7. PubMed ID: 16265674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.